In one aspect, the present disclosure provides a microRNA-33 (miR-33) inhibitor comprising a peptide nucleic acid covalently bound to a pH low insertion peptide. In another aspect, the present disclosure provides a method of treating pulmonary fibrosis in a subject, the method comprising administering to the subject a therapeutically effective amount of the miR-33 inhibitor. In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
2.
LOW-DIMENSIONAL METAL-HALIDE PEROVSKITES FOR INFRARED, TETRAHERTZ, AND MILLIMETER-WAVE LIGHT DETECTION
Described herein is a construct including an FGF21 polypeptide, which includes residues 186-198 and residues 200-209 of FGF21. The FGF21 polypeptide includes one or more mutations that confers FGF21 polypeptide stronger affinity with β-Klotho as compared with a corresponding wild-type FGF21 polypeptide. Also described herein is a composition including the construct, as well as methods of modulating the FGF21/FGFR/β-Klotho signaling pathway or the FGF19/FGFR/β-Klotho signaling pathway and methods of treating, ameliorating and/or preventing diseases or disorders associated with mis-regulation (such as up- or down-regulation) of the signaling pathways.
The present invention relates to the development and fabrication of thin-film polymer composite materials containing vertically aligned nanopores. The present invention provides methods of aligning nanopores in a polymeric film. The present invention also provides composite materials and methods of fabricating composite materials containing vertically aligned nanopores.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
B01D 71/40 - Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
B05D 1/00 - Processes for applying liquids or other fluent materials
B05D 3/00 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials
B05D 3/04 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to gases
B05D 3/06 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by exposure to radiation
B32B 17/10 - Layered products essentially comprising sheet glass, or fibres of glass, slag or the like comprising glass as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
5.
HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY
This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Described is an active layer having a first surface region and a bulk region, the active layer comprising a small molecule component and a polymer component, wherein the relative concentration of the small molecule component is lower in the first surface than in the bulk region. Also described is a method of producing a surface-modified active layer comprising the steps of providing a pristine active layer comprising a small molecule component and a polymer component; applying an adhesive to the exposed surface of the pristine active layer to produce an adhesive-bound active layer; and removing the adhesive from the adhesive-bound active layer, and a method of producing electrical energy from sunlight, such as sunlight deposited over bodies of water.
H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
8.
METHODS FOR SELECTIVELY REDUCING IMMUNOGENICITY IN A TRANSPLANT
The present invention relates to methods for reducing or eliminating reactive T cells from a transplant or a part thereof prior to transplantation. The present invention also relates to methods for reducing immunogenicity in a transplant or a part thereof prior to transplantation. The present invention further relates to transplants obtained by the described methods and apoptotic agent treated transplants for use in reducing or preventing inflammatory conditions such as graft-versus-host disease. Specifically, the methods can be used to reduce graft versus host disease following transplantation.
Systems and methods for implementing holographic quantum circuits on compact quantum computing systems are provided. Compact quantum computing systems include systems having fewer physical qubits than the number of quantum modes to be instantiated during execution of the quantum circuit. Techniques described herein may be used to perform boson sampling techniques, including with application to molecular docking simulations.
Disclosed herein is a method of treating cancer in a subject in need thereof. The method comprises determining a first level of a first cancer-specific antigen in a cancer sample of the subject; determining a second level of a second cancer-specific antigen in the cancer sample; and administering to the subject a first antibody-drug conjugate (ADC) targeting the first cancer-specific antigen or a second ADC targeting the second cancer-specific antigen based on the levels of the two cancer-specific antigens. Also disclosed herein is a method of constructing a cancer antigen level standard, which can be used in the selection of ADCs.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Institute for Research in Biomedicine (IRB) (Switzerland)
Inventor
Murphy, Andrew J.
Stevens, Sean
Rathinam, Chozhavendan
Eynon, Elizabeth
Manz, Markus
Flavell, Richard
Yancopoulos, George D.
Abstract
Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.
The present disclosure generally relates to compositions, methods, and kits for the identification of diagnostically and therapeutically relevant proteins. In some instances, the identification of the diagnostically and therapeutically relevant proteins can be used to aid in treatment of a subject in need thereof.
The present disclosure relates to the introduction of expression constructs encoding different gene products such as proteins or nucleic acids at defined ratios into host cell lines containing multiple dock sites for insertion of the nucleic acid construct, and to the production of proteins that require expression of at least two gene products.
Compositions and methods for targeted ubiquitination of the voltage-gated sodium channel Nav1.8. The compositions include a bifunctional molecule that includes two bioactive domains, a first bioactive domain for selective binding to Nav1.8 channels and a second bioactive domain for which can be has the activity of (i) catalyzing a ubiquitination reaction to tag the channel for internalization and degradation, (ii) recruitment and binding of a ubiquitin ligase which then catalyzes a ubiquitination reaction to tag the channel for internalization and degradation or (iii) l recruitment of the fusion protein to lysosomes. The bifunctional molecule includes a HECT domain from NEDD4 ubiquitin ligase and includes a myosin tail domain (MTD) from clathrin linker-1 (SCLT-1), functional fragments or variants thereof, provide the two bioactive domains. The compositions are administered to a subject in need thereof, in an effective amount to treat acute chronic pain.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
16.
METHODS OF DETECTING VIRAL OR BACTERIAL INFECTIONS
In one aspect, the invention provides a method for detecting a viral-only or a bacterial-associated respiratory infection in a patient, the method comprising analyzing a respiratory sample to determine levels of at least two respiratory virus infection-associated molecules, at least two bacterial respiratory infection-associated molecules, and comparing the levels of the respiratory virus infection-associated molecules and/or the levels of the bacterial respiratory infection-associated molecules with a predetermined reference level.
In one aspect, described herein is a method of treating, ameliorating, and/or preventing a stress-related disorder in a subject in need thereof. In certain embodiments, the method includes administering to the subject a therapeutically effective amount of a α1A-adrenergic receptor subtype selective inhibitor.
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
18.
PASSIVELY ADAPTIVE LEGGED ROBOT WITH DIFFERENTIALS AND NON-BACKDRIVABLE PRISMATIC LEGS
A legged robot system has a medial body with first and second ends, slidably and rotatably attached to a lateral body with first and second ends via a locomotion mechanism configured to provide at least first and second degrees of freedom of movement for the lateral body relative to the medial body, a plurality of prismatic legs extending downward from positions on the lateral or medial bodies, each leg having a drive mechanism for extending the leg, wherein the first leg provides a third degree of freedom relative to its position on the lateral or medial body, and the second leg provides a fourth degree of freedom relative to its position on the lateral or medial body, and a differential mechanism connecting the first and second legs providing a fifth degree of freedom of movement for the first and second leg relative to each other.
B62D 57/032 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members with alternately or sequentially lifted supporting base and legVehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members with alternately or sequentially lifted feet or skid
B25J 9/10 - Programme-controlled manipulators characterised by positioning means for manipulator elements
19.
MODIFIED BOTTLEBRUSH BLOCK COPOLYMERS WITH SELECTIVE TISSUE UPTAKE
A method to precisely tailor the surface topography of polymeric nanoparticles having bound thereto polyalkylene oxide and to improve their systemic circulation and diseased tissue accumulation, based on tuning the architecture of shape-persistent amphiphilic bottlebrush block copolymer (BBCP) building blocks and inclusion of small molecule chemical modifications, has been developed. It was demonstrated that nanoparticle formation and surface topography can be controlled by systematically changing structural parameters of BBCP architecture. The surface topography of PEGylated nanoparticles (nanoparticles having PEO or PEG covalently bound thereto) and the presence of hydrophobic small molecule modifications, cationic small molecule modifications, and/or small molecule modifications containing a positively ionizable atom significantly affects their biological performance.
A fabric capacitive strain sensor integrated into everyday clothing to measure human motions. The sensor is made of thin layers of breathable fabrics and exhibits high strains, excellent cyclic stability, and high water vapor transmission rates, which allows for sweat evaporation. The sensor's functionality is evaluated under conditions similar to those experienced on the surface of the human body (35° C. and 90±2% relative humidity) and after washing with fabric detergent. The fabric sensor shows stable capacitance at excitation frequencies up to 1 MHz.
D03D 1/00 - Woven fabrics designed to make specified articles
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
H05K 3/02 - Apparatus or processes for manufacturing printed circuits in which the conductive material is applied to the surface of the insulating support and is thereafter removed from such areas of the surface which are not intended for current conducting or shielding
The present invention provides compositions and methods comprising an activator of interleukin-18 (IL-18) activity for use in therapeutic and non-therapeutic applications. The activator provides IL-18 signaling activity even in the presence of an inhibitory molecule 5 such as IL-18 binding protein (IL-18BP).
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 35/768 - Oncolytic viruses not provided for in groups
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Systems and methods for performing fault tolerant quantum operations for the 4-legged cat code are provided. The quantum systems include an ancilla qubit dispersively coupled to a first logical qubit. and the quantum system may be operated at least in part by: generating and applying a first drive waveform to the ancilla qubit. the first drive waveform comprising a first comb of 7t-pulses having selective frequencies corresponding to a first selection of even and odd cavity resonance frequencies of the first logical qubit: and reading out a state of the ancilla qubit.
Provided herein are a method of preparing a Titanium:Sapphire (Ti:Sa) wafer and a photonic circuit integrated (PIC) Titanium:Sapphire (Ti:Sa) laser. The method includes depositing a titanium layer on a top surface of a first sapphire substrate; positioning a second sapphire substrate on the titanium layer, forming a face-to-face configuration with the titanium layer between the first and second sapphire substrates; annealing the first and second sapphire substrates in the face-to-face configuration, forming an annealed substrate; and polishing the annealed substrate, forming a polished substrate. The PIC-Ti:Sa laser includes a substrate; a waveguide formed on the substrate, the waveguide including a microring portion; a Ti:Sa layer formed over the microring portion of the waveguide, the Ti:Sa layer and the microring portion of the waveguide forming a microring cavity; and a laser source coupled to the waveguide. Also provided herein are methods of forming a photonic circuit integrated mode-locked Ti:Sa laser.
G02B 6/42 - Coupling light guides with opto-electronic elements
H01S 3/08 - Construction or shape of optical resonators or components thereof
H01S 3/0941 - Processes or apparatus for excitation, e.g. pumping using optical pumping by coherent light of a semiconductor laser, e.g. of a laser diode
24.
ANTIBODIES HAVING PAN-ANTIVIRAL ACTIVITY AND METHODS THEREOF
Described herein are antibodies having pan-antiviral activity. In certain embodiments, the antibodies recognize glycosylation patterns specific to viral proteins, but not found on host proteins. Also described herein are methods of preventing, treating, and/or ameliorating viral infections using the antibodies of the disclosure.
The invention relates to methods of evaluating the quality of a batch of an herbal composition, the method comprising subjecting a test batch of the herbal composition to one or more biological analysis methods and comparing the results derived from the test batch to the results of a known batch of herbal composition which has a known in vivo effect.
Described herein is an mRNA molecule including a 5'-cap analog, a 5'-untranslated region (5'-UTR), and a coding sequence. The translational enhancer sequence, when combined with the 5'-cap analog, increases a translational efficiency of the mRNA. Also described herein is a method of modulating a translational efficiency of an mRNA molecule based on the construction of the mRNA molecule herein, as well as a method of expressing a polypeptide or a protein using the mRNA molecule herein.
An ultra-high vacuum instrument, comprising a vacuum chamber, a sample storage stage, a non-evaporable getter and/or ion pump connected to the vacuum chamber to reduce the ambient pressure in the vacuum chamber, and at least one vacuum port including connection hardware adapted to connect to a sputtering gun for cleaning a sample surface or an evaporator for supplying material to grow a film on a sample. The sample storage stage, in some embodiments, includes a first sample parking position, a heating element adapted to apply heat to a sample loaded in the first sample parking position, one or more second sample parking positions, and a thermal insulating plate positioned to insulate the second sample parking positions from heat generated by the heating element.
H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
H01J 41/12 - Discharge tubes for evacuating by diffusion of ions, e.g. ion pumps, getter ion pumps
H01J 7/18 - Means for absorbing or adsorbing gas, e.g. by gettering
H01J 19/70 - Means for obtaining or maintaining the vacuum, e.g. by gettering
H01J 41/16 - Discharge tubes for evacuating by diffusion of ions, e.g. ion pumps, getter ion pumps with ionisation by means of thermionic cathodes using gettering substances
Topical formulations have been developed which have been demonstrated to reduce ultraviolet ("UV")-induced cyclobutane pyrimidine dimer ("CPD") formation in a human clinical trial. The formulation includes all natural, non-toxic compounds which can be utilized in sunscreens, cosmetics and hair conditioners to protect from ultraviolet radiation. A preferred embodiment of the formulation contains 10% Ferulic Acid, 10% Diosmin, 5% Cytisine and 5% Resveratrol. A method of screening for compounds that are safe and effective to reduce UV-induced CPD formation also has been developed.
A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
29.
METHODS AND COMPOSITIONS FOR PROLONGED RENALASE AGONIST ACTIVITY
Administration of recombinant or biologically-isolated renalase has been shown to treat certain diseases and conditions. Stable synthetic peptides exhibiting renalase agonist activity are highly desirable. Disclosed are compositions comprising modified renalase agonist peptides that display increased in vitro and/or in vivo half-life, and methods for their use in treating diseases such as ischemic and toxic organ injury.
An electrolytic device, photoelectrode, and method for inducing an electrochemical reduction of a feed gas, comprising an anode and a hybrid cathode, the hybrid cathode comprising a cathode, a microporous layer disposed on one side of the cathode; a cathode catalyst positioned on the surface of the microporous layer, a gas channel fluidly connected to the microporous layer, containing a quantity of a feed gas, an electrolyte channel fluidly connected to the cathode catalyst containing a quantity of electrolyte, wherein the hybrid cathode is configured to induce an electrochemical reaction in the feed gas to produce methanol, and wherein the cathode catalyst comprises a compound represented by General Formula (I).
C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material
C25B 11/051 - Electrodes formed of electrocatalysts on a substrate or carrier
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
31.
COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE SKIN DISEASES
Methods of treating autoimmune skin diseases and disorders are provided. The methods typically include administrating to a subject with an autoimmune skin disease or disorder an effective amount of a hypoxia-inducible factor-1 (HIF-1) inhibitor. In preferred embodiments, the autoimmune disease is mediated at least in-part by T cells, particularly skin-infiltrating T cells. In some embodiments, the subject has cutaneous lupus (e.g., discoid cutaneous lupus, subacute cutaneous lupus, acute cutaneous lupus), pemphigus, pemphigoid, epidermolysis bullosa acquisita, vitiligo, lichen planus, lichen sclerosus, dermatomyositis, alopecia areata, or Sjögren's syndrome. HIF-1 inhibitors and pharmaceutical compositions including the same for use in the disclosed methods are also provided. The HIF-1 inhibitor can be, for example, a small molecule, functional nucleic acid, or inhibitory polypeptide or protein. The pharmaceutical composition can be formulated to suitable for the type and mode of administration, e.g., systemically or locally to skin effected by the autoimmune disease.
A computer-implemented method of increasing appointment attendance comprises providing a processor and a non-transitory memory including computer program code for one or more programs, the memory and the computer program code configured to, with the at least one processor, perform steps comprising obtaining an appointment data structure, comprising an attendee and a corresponding appointment for the attendee, obtaining a set of population data, obtaining a set of appointment data, obtaining a set of external data, obtaining environmental data, inferring, using the population data, the appointment data, the external data, and the environmental data in a machine learning algorithm, a probability that the attendee will attend the appointment, and when the probability of attendance is below a threshold, performing a mitigation step to increase the probability that the attendee will attend the appointment. A system for increasing appointment attendance and a non-transitory computer-readable medium containing computing instructions are also described.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
33.
MACHINE LEARNING SYSTEM AND METHODS FOR INCREASING APPOINTMENT COMPLIANCE
A computer-implemented method of increasing likelihood of appointment completion comprises providing at least one processor; and at least one non-transitory memory including computer program code, configured to perform steps comprising obtaining an appointment data structure comprising an attendee and a corresponding appointment for the attendee, obtaining data comprising at least one of a set of population data, a set of appointment data, a set of external data, or environmental data, wherein the data comprises at least two different formats, standardizing the at least two different formats of data, inferring, using the standardized data in a machine learning algorithm by the at least one processor and the at least one non-transitory memory, a probability that the attendee will complete the appointment, and when the probability of completion is below a threshold, performing a mitigation step to increase the probability that the attendee will complete the appointment.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
34.
IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE
The compounds of Formula I described herein regulate activity of JAK2 by specifically binding to the JAK2 pseudokinase domain, JH2, and are useful as therapeutic agents in the treatment or amelioration of myeloproliferative disorders. Also provided herein are methods of treating myeloproliferative disorders, and methods of making compounds of Formula I.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention provides microglial cell comprising cortical organoid cultures, methods of generating the same and methods of use thereof for identifying therapeutic agents.
Quantum systems and techniques are described to generate fault tolerant cluster states for use in quantum computation, quantum networking, and other applications. The systems and techniques include initializing states in first qubits and generating initial resource states by performing first Pauli product measurements on sets of X-type and/or Z-type qubits of the first qubits, the initial resource states comprising qubit cluster states comprising at least three qubits. The final cluster state may then be generated by fusing two or more initial resource states, the fusing comprising performing second Pauli product measurements between qubits of two or more of the initial resource states.
Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.
Described herein is a probe for monitoring specific RNA splicing events, with utility for identifying molecular modulators of RNA splicing. The probe includes a nucleic acid, a first fluorescent element attached to a first end of the nucleic acid, and a second fluorescent element attached to a second end of the nucleic acid. The fluorescence signal of the probe changes when the probe hybridizes with either a pre-splicing RNA molecule or a splicing product. Also described herein is a method of monitoring RNA splicing and a method of screening of modulators of RNA splicing using the probe.
C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
YALE UNIVERSITY (USA)
Inventor
Jin, Jian
Xiong, Yan
Park, Kwang-Su
Velez, Julia
Liu, Jing
Chen, Xian
Song, Juan
Xie, Ling
Sheehy, Ryan N.
Jiang, Yonghui
Wang, Sung-Eun
Abstract
Described is small molecule N-(l-isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7- (3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) that inhibits methyltransferases G9a/GLP. This inhibitor can be used for the treatment of patients with G9a/GLP related diseases such as Alzheimer's Disease and Prader-Willi Syndrome.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
40.
METHODS FOR IDENTIFYING CARDIOVASCULAR DISEASE FROM RETINAL SCANS
It has been established that the presence of RIPLs is associated with higher prevalence of stroke, and especially in patients with atrial fibrillation. Enhanced methods for the detection and quantitation of retinal ischemic perivascular lesions (RIPLs) from commonly used OCT scans which are widely used in optometry and ophthalmology clinics are described. Systems and methods to characterize disease state and risk of stroke based on the identification and quantitation of RIPLs in the eyes of patients having atrial fibrillation have been developed. Methods of using information obtained according to the described methods to guide patient stratification for anticoagulation therapy are provided. Methods of identifying RIPLs from OCT scans are provided.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
41.
COLIBACTIN DERIVATIVES AND METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING CANCER
Described herein is a stable colibactin derivative, or a salt, solvate, isotopically labelled derivative, stereoisomer, tautomer, or geometric isomer thereof, or any mixtures thereof. Also described herein is a method of alkylating a DNA molecule, a method of forming a DNA interstrand cross-link (ICL), as well as a method of preventing, treating, and/or ameliorating cancer.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
42.
METHODS USING WNT AND SHH AGONISTS TO STIMULATE HAIR FOLLICLE GROWTH
Dkk1Dkk1+ progenitors transiently amplify to become quiescent dermal condensate cells by the spatiotemporal patterning of Wnt/β-catenin and sonic hedgehog ("SHH") signaling gradients. Together, they deterministically coordinate a rapid transition from proliferation to quiescence, cell fate specification, and morphogenesis. This is useful for screening to discover compounds that can be administered to hair follicles to stimulate hair growth (new hair follicles) and restore hair follicle size. These agonists of Wnt and SHH are formulated for application to skin to grow hair.
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
A61K 8/00 - Cosmetics or similar toiletry preparations
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61Q 7/00 - Preparations for affecting hair growth
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
43.
DEVICE AND METHOD FOR POST EXTUBATION DYSPHAGIA, ANTIBACTERIAL THERAPY, AND DETECTION AND DRAINAGE OF PHARYNGEAL SECRETIONS
A drainage device includes an elongate flexible conduit comprising a proximal end opening, a distal end opening and a lumen disposed therebetween. A multi-layer distal portion coaxially surrounding the lumen and having a porous outer surface layer, a porous interior layer and an intermediate absorbent layer therebetween. A drainage system and a device and method for treating dysphagia are also disclosed.
44.
METHODS FOR SENSITIZING DRUG-RESISTANT CANCER CELLS
The present invention is directed to methods of sensitizing tyrosine kinase inhibitor (TKI)-resistant cancer cells in a subject using a SWI/SNF complex modulator.
Described herein is a method of reversing or preventing a formation or enlargement of an axonal spheroid. The method includes introducing into a neuron affected by formation or enlargement of the axonal spheroid a compound that downregulates PLD3 expression level or activity. Also described herein is a method of treating or preventing a neurodegenerative condition in a subject in need thereof. The method includes administering to the subject a compound that downregulates PLD3 expression level or activity in a neuron cell affected by the neurodegenerative condition. Further described herein is a pharmaceutical composition for treating a neurodegenerative condition in a subject. The pharmaceutical composition includes a compound that downregulates PDL3 expression level or activity in a neuron cell affected by the neurodegenerative condition; and a pharmaceutically acceptable carrier.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective/significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.
Methods of isolating and sequencing aberrant expansion-specific RNA sequences using antisense oligonucleotides (ASO) specific for repeat-containing RNAs have been established. The methods isolate repeat-containing RNAs from RNA using hybridization probes specific for repeat-containing sequences. Typically, RNA capture is performed by preferential hybridization of repeat-containing RNAs to a multiplicity of immobilized probes. The methods isolate expansion-specific RNAs and determine the sequences of aberrant splice variants associated with diseases and disorders. In other forms, the methods identify small molecules that selectively target the pathological splice variant transcripts. In some forms, the methods provide expansion-specific ASOs that specifically target and eliminate the pathological splice variant transcripts in vivo. Compositions of ASOs that specifically target and eliminate the pathological splice variant transcripts are also provided.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
48.
CHEMOTHERAPEUTIC BIOADHESIVE PARTICLES WITH IMMUNOSTIMULATORY MOLECULES FOR CANCER TREATMENT
A bioadhesive nanoparticle (BNP) for long-lasting local drug delivery to treat cancer was developed. The bioadhesive nanoparticles (BNP) are composed of biodegradable polymer such as poly(lactic acid)-hyperbranched polyglycerol (PLA-HPG), encapsulating a chemotherapeutic such as camptothecin (CPT). Nanoparticles (NPs) of PLA-HPG are non-adhesive NPs (NNPs), which are stealthy in their native state, but conversion of the vicinal diols of HPG to aldehydes confers the ability to form strong covalent bonds with amine-rich surfaces. The formulation is administered in combination with immunostimulatory molecules such as CPG and shows unexpectedly better killing of cancer cells.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Various semiconductor structures containing buried tunnel junctions or aperture regions are described. Further disclosed are methods for preparing and using such semiconductor structures which can be used, for example, in optoelectronic devices, such as vertical cavity surface emitting lasers (VCSELs), which can emit at long wavelengths.
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
50.
BOTTLEBRUSH BLOCK COPOLYMER-LIPID FOR THE FORMATION OF LIPID NANOPARTICLES WITH ROUGH SURFACE TOPOGRAPHY
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
51.
REMOVAL OF AQUEOUS POLY AND PERFLUOROALKYL SUBSTANCES BY COVALENT TRANSFORMATION TO INSOLUBLE FLUORINATED ESTER
Poly arid perfluoroalkyl substances (PFAS) are toxic, ubiquitous contaminants in the environment along with drinking and waste water systems. Current treatment approaches struggle to effectively treat PEAS molecules without generating large amounts of toxic waste or requiring large energy and/or material inputs. With addition of alcohol such as decanol alone, PFAS such as water-soluble perfluorooctanoic acid (PFOA), can be transformed into a water-insoluble, fluorinated ester(s) that precipitate out of solution, facilitating self-removal. Highly hydrophobic fluorinated tails allow for esterification to proceed in water without the addition of any surfactant.
The present disclosure generally relates methods and compositions comprising VEGF-D, which methods and compositions can be used in the treatment of respiratory disorders. In some instances, the methods and compositions can be used for treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).
Provided herein are methods of training an algorithm for adaptive predictive enrichment of a randomized controlled trial (RCT). The method includes providing an RCT with at least one primary outcome; defining an interim analysis timepoint; at the interim analysis timepoint, defining individualized estimates of the effects of a studied intervention for the primary outcome, as compared to a control arm, through iterative analysis; and training a machine-learning algorithm to identify one or more signatures of individualized treatment response in a treatment group as compared to a control group; where the one or more signatures of individualized treatment response are used to recommend predictive enrichment for subsequent RCT enrollment. Also provided herein is a method of adaptive predictive enrichment of a RCT including applying the algorithm trained above.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present invention provides cationic polymeric nanoparticles, and nanoparticle formulations thereof. The invention also provides methods for preparing cationic polymeric nanoparticles, and methods of treating diseases, reducing tumor growth, and increasing uptake of a therapeutic agent by a tumor cell in a subject in need thereof.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
55.
Identification and Treatment of Cancers Associated with RASGRF1 Gene Fusions
The disclosure provides compositions and methods for identifying a cancer associated with an RASGRF1 gene fusion in a subject. The disclosure also includes methods of treating a subject who has been pre-selected by detecting an RASGRF1 gene fusion in a sample obtained from the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
56.
TECHNIQUES FOR QUANTUM ERROR CORRECTION USING MULTIMODE GRID STATES AND RELATED SYSTEMS AND METHODS
Techniques are described for implementing a class of multimode bosonic codes that protect against errors within an ancilla qubit coupled to a bosonic system, that can be realized experimentally. A logical qubit state is represented by the states of multiple different modes of one or more bosonic systems, which may include multiple modes of a single bosonic system and/or single modes from multiple bosonic systems. Techniques for correcting errors are also described. In particular, a series of operations are described that autonomously detect and correct errors by repeatedly performing a sequence of operations that are each applied to the multiple bosonic modes and/or to the ancilla qubit that is coupled to each of the bosonic modes. The codes allow ancilla errors to propagate to the modes of the bosonic system as correctable errors, where they can be corrected, instead of presenting as logical errors in the ancilla qubit.
Provided herein are methods for communicating data between nodes in a computer system and distributed systems of computer architectures. The methods include generating a hash based upon a data set, communicating the hash to one or more nodes, comparing the communicated hash to stored hashes at the one or more nodes, and communicating the data set when matching hashes are detected. The system includes two or more processing elements configured to communicate data according to the methods above.
Provided is an adsorbent for removing perfluoroalkyl and polyfluoroalkyl substances from an aqueous solution, including perfluoro-octanoic acid (PFOA), perfluoro-octane sulfonate (PFOS), shorter-chained perfluoroalkyl and polyfluoroalkyl substances, and combinations of foregoing. The adsorbent includes iron oxide nanocrystals, wherein the absorbent has an adsorption capacity for PFOA of at least 5000 mg/g or an adsorption capacity for PFOS of at least 25,000 mg/g. Also provided are methods of removing contaminants from an aqueous solution, wherein the contaminants include perfluoroalkyl and polyfluoroalkyl substances.
60.
METHODS FOR THE TREATMENT AND PREVENTION OF NON-VIRAL TICK-BORNE DISEASES AND SYMPTOMS THEREOF OF
Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.
The present invention provides methods for bioprinting collagen and extracellular matrix-based bioinks, and articles such as engineered tissues, comprising the bioinks. In other aspects, the present invention relates to a bioprinting system including a 3D bioprinter with a nozzle, at least one bioink, a support bath solution, wherein the support bath solution comprises PEG (polyethylene glycol) and agarose.
Benaroya Research Institute at Virginia Mason (USA)
Yale University (USA)
Inventor
Leon, Francisco
Herold, Kevan C.
Long, Sarah Alice
Linsley, Peter S.
Abstract
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T-cells, which is indicative of successful prevention or delay of the onset of clinical T1D.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
Provided are digitally-implemented methods of treating a mental health issue in a subject. The methods include digitally delivering a standardized assessment to the subject; analyzing data collected from the standardized assessment; identifying an evidence-based treatment pathway based upon the analysis of the data; and administering the evidence-based treatment pathway to the subject.
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61B 5/16 - Devices for psychotechnicsTesting reaction times
Aspects of the present invention relate to a system including a transformer encoder with a compression layer, a transformer decoder with an expansion layer, the transformer encoder configured to transform one or more inputs into a control latent vector, a noise injection element configured to add noise to the control latent vector to create a noisy latent vector, a weighting element configured to add one or more weightings to the control latent vector to create an exact latent vector, and the transformer decoder configured to transform the noisy latent vector and exact latent vector into an output.
G16C 20/70 - Machine learning, data mining or chemometrics
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
65.
METHODS OF IDENTIFYING CIS-REGULATORY ELEMENTS OF TRANSLATION
Described herein is method of identifying cis-regulatory element of translation. The method includes: translating a plurality of mRNA molecules, each comprising a potential cis-regulatory element, with ribosomes to obtain a mixture; generating from the initial mixture an enriched mixture comprising mRNA molecules being translated, the ribosomes, and partial translation products being produced by the ribosomes from the mRNA molecules, according to affinity of the partial translation products to a binding partner thereof; sequencing the mRNA molecules present in the enriched mixture; determining an abundance of each mRNA molecule present in the enriched mixture; and identifying cis-regulatory elements of translation based on the determined abundance of each of the plurality of mRNA molecules. Also described herein is a method of determining translational efficiency of an mRNA molecule that includes similar steps.
66.
METHOD OF PREDICTION OF LIGAND-PROTEIN BINDING AFFINITIES USING META-MODELS
Provided herein are methods of developing a meta-modeling framework for ligand-protein binding affinity prediction by integrating empirical scoring function-based docking and deep learning-based regression outputs through linear and non-linear machine learning models. Thus, empirical docking models and deep learning models were used as base models data. By taking predictions from those base models, machine learning regression models were developed as meta-models. These meta-models significantly improve binding affinity prediction over individual base models and achieve comparable performance to other structure-based deep learning models.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
Provided herein are methods of training and building algorithms to predict stroke etiology. The method of training an algorithm to predict stroke etiology includes processing electronic health records (EHRs) in a derivation dataset, the processing including extracting clinical variables from the EHRs by detecting concept unique identifiers (CUIs) through natural language processing (NLP), and extracting other covariates from the EHRs through regular expression, wherein the clinical variables and other covariates form a training dataset; training two or more base models with the training set to form two or more trained base models, the base models selected from the group including Random Forests (RF), XGBoost (XGB), support vector classifier (SVC), and logistic regression (LR); refining the two or more trained base models using hyperparameters to form two or more refined base models; and building an ensemble model with the two or more refined base models. Also provided herein are articles and methods of predicting ischemic stroke etiology using the trained algorithm.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G06F 18/214 - Generating training patternsBootstrap methods, e.g. bagging or boosting
68.
COMPOUNDS AND METHODS FOR TREATING CANCERS THAT ARE MGMT DEFICIENT REGARDLESS OF MMR STATUS
Disclosed are compounds and methods of treating, ameliorating, and/or preventing cancers, including cancers that are MGMT deficient regardless of their MMR status, and particularly compounds and methods of treating, ameliorating, and/or preventing cancers that are both MGMT and MMR deficient or that are MGMT deficient and resistant to treatment with temozolomide.
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
PC1-CTT polypeptides for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) are provided and can be or include PC1-CTT (SEQ ID NO:1) or a functional fragment or variant thereof. In some embodiments, the PC1-CTT polypeptide is a fusion protein or conjugate further including a functional element such as a protein transduction domain, fusogenic polypeptide, targeting signal, or expression and/or purification tag. Nucleic acids encoding the disclosed PC1-CTT polypeptides and other therapeutic proteins are also provided. In some embodiments, the nucleic acid encodes a TOP or TOP-like motif. The nucleic acids can be RNA or DNA, and can be, for example, a vector such as a plasmid or viral vector, or an mRNA. Methods of treatment are provided and typically include administering a subject in need thereof an effective amount of a disclosed polypeptide or nucleic acid.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An imaging method calculates T2 maps using only data from a T2w image scan. The imaging system is used in conjunction with an MRI system that includes a magnet housing, a superconducting magnet, shim coils, RF coils, receiver coils, a patient support, and measurement circuitry producing data used to reconstruct images displayed on a display. The measurement circuitry integrates either expanding-constrained alternating minimization for parameter mapping or expanding-constrained alternating minimization for parameter mapping with projected gradient descent.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Described herein is a non-natural mRNA molecule, which includes a non-natural cisregulatory element that modulates the translational efficiency of the mRNA molecule. Also described herein is a method for modulating mRNA translational efficiency.
72.
SYSTEM AND METHOD FOR INTEGRATED LIFESTYLE MEDICINE
A system for integrated lifestyle medicine tracking and digital therapy comprises a central computing system comprises a device interface subsystem, a user data interface subsystem, a data visualization engine, and a set of instructions, which when executed by the processor, perform steps comprising collecting a first data stream from the at least one sensor via the device interface subsystem, collecting a first user-reported data stream from the at least one user via the user data interface subsystem, calculating a probability of at least one lifestyle risk factor from the first data stream and the first user-reported data stream, and presenting the user with at least one intervention to mitigate the at least one lifestyle risk factor. A method for integrated lifestyle medicine tracking and digital therapy is also disclosed.
G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
The present invention relates to fiber jamming systems capable of tuning tensile stiffness of soft systems within seconds without the use of high voltage or temperature changes. The systems employ segmented fibrils of interspersed segments of stretchable and non-stretchable materials. Applying a vacuum to the fibrils in an enclosed volume elicits a large interfacial shear resistance to tensile displacement. In the absence of a vacuum, the fibrils are free to stretch and bend in any direction.
D01F 8/14 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from synthetic polymers with at least one polyester as constituent
A scanning electron microscopy (SEM) system performs subvoxel microscopy with a probe and detector. The probe directs incoming probe electrons at a sample with an energy and a direction. The detector detects electrons scattered by the sample and generates a two-dimensional energy profile map of the detected electrons. The system may determine subvoxel information including features of the sample smaller than a size of the probe using the energy and direction and the two-dimensional energy profile map. The system may determine three-dimensional subvoxel information of the sample. The system may be a focused ion beam scanning electron microscopy (FIB-SEM) system with an emitter directing a FIB at the sample to separate layers thereof. For each of multiple layers, the system may obtain the energy and direction and generate the two-dimensional energy profile map. The system may generate three-dimensional subvoxel volume information of the sample thicker than individual layers.
75.
Protein Capture Membrane and Method of Use Thereof
In one aspect, the invention provides a protein capture membrane comprising a first side and a second side and a plurality of interstices extending contiguously from the first side to the second side, wherein the interstices are coated with a protein-reactive coating; and the porous substrate comprises nanoporous alumina or porous glass. In another aspect the invention provides a method of detecting a protein of interest in a plurality of proteins.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
B01D 57/02 - Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. by electrophoresis
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
It has been determined that differential methylation at CpG loci can be used to determine the severity of lupus nephritis (LN). Thus, differentially methylated CpG loci (also referred to herein as biomarkers), as well as methods of detecting methylation at the biomarkers are provided, as are their use to determine the severity of LN and inform treatment. In particular, the differential methylation is useful in distinguishing patients with class II LN from patients suffering from LN of classes III - VI and thereby determining whether the patient should be given immunosuppressants.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Described herein are methods of modulating mRNA translational efficiencies with translational enhancers or silencers that affects ribosomal retention. Also described herein are mRNA molecules including translational enhancers or silencers, as well as modified nucleobases. Also described herein are methods of constructing an mRNA molecule for producing a therapeutic peptide or a therapeutic protein with the identified enhancers.
78.
EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE
The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered 10 lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
Fusion proteins including (a) a mast cell intracellular signaling domain; and (b) an amino acid sequence that is heterologous to the mast cell intracellular signaling domain are provided. In some embodiments, (a) includes the intracellular domain of IgE receptor (FcεRI), a cytokine receptor (c- KIT), a G-protein-coupled receptor, or a toll-like receptor expressed in mast cells, or functional fragment or variant thereof. In some embodiments, the amino acid sequence of (a) includes an ITAM sequence. In preferred embodiments, the fusion proteins are chimeric antigen receptors (referred to as "CAR-mast"), that include a transmembrane domain and an extracellular domain that targets an antigen. Nucleic acids encoding the fusion proteins, and mast cells including or expressing the nucleic acids and/or fusion proteins are also provided, as are methods of the using the same to treat diseases and disorders characterized by expression of the antigen.
The invention provides a system for hypothermic, restoration and preservation of organs in a mammal. In certain aspects, the system is capable of preserving organs, maintaining cellular integrity and cellular function for hours postmortem or after global ischemia. The invention also provides synthetic organ perfusate formulations, including a novel perfusate autologous blood mixture, which is able to reduce reperfusion injury, stimulate recovery from hypoxia, metabolically support the energy needs of organs and prevent rigor mortis.
Examples described herein provide a computer-implemented method that includes receiving a noninvasive transabdominal fetal electroencephalography (TA-fEEG) signal associated with a pregnant subject. The method further includes reducing unwanted noise in the TA-fEEG signal using a first machine learning model. The method further includes reconstructing a fetal electroencephalography (fEEG) signal from the TA-fEEG signal using a second machine learning model.
G06F 18/2134 - Feature extraction, e.g. by transforming the feature spaceSummarisationMappings, e.g. subspace methods based on separation criteria, e.g. independent component analysis
The present disclosure provides methods of making and methods of using IL-18 mimic polypeptides for use in therapeutic and non-therapeutic applications. The synthetic IL-18 mimics an increase IL-18R signaling activity even in the presence of an inhibitory molecule such as IL-18BP.
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
YALE UNIVERSITY (USA)
GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE (USA)
Inventor
Diddams, Scott A.
Quinlan, Franklyn J.
Liu, Yifan
Kelleher, Megan L.
Mclemore, Charles A.
Rakich, Peter Thomas
Jin, Naijun
Abstract
A vacuum-gap optical cavity includes a spacer having a first spacer surface and a second spacer surface, a first mirror having a first reflective coating formed on a first substrate, and a second mirror having a second reflective coating formed on a second substrate. The spacer forms a cavity region that extends between a first aperture at the first spacer surface and a second aperture at the second spacer surface. The first mirror is bonded to the first spacer surface such that the first reflective coating overlaps the first aperture and such that the first mirror completely covers the first aperture. The second mirror is bonded to the second spacer surface such that the second reflective coating overlaps the second aperture and such that the second mirror completely covers the second aperture. The cavity region is maintained under vacuum without active pumping.
H01S 3/08 - Construction or shape of optical resonators or components thereof
H01S 5/10 - Construction or shape of the optical resonator
G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
H01S 5/06 - Arrangements for controlling the laser output parameters, e.g. by operating on the active medium
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
86.
Cell-Penetrating Peptides and Methods of Use Thereof
In various aspects and embodiments the invention provides compositions and methods for facilitating cell penetration of a cargo molecule. In another aspect, the invention provides a method of preventing viral infection in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a polypeptide comprising a cell-penetrating peptide and a retromer binding site.
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
C07D 261/08 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
88.
METHODS OF ACQUIRING MICROSCOPIC IMAGES OF BIOLOGICAL SAMPLES
Described herein is a method of acquiring a microscopic image of a biological sample. In certain embodiments, the method includes at least one of the following: the method including: embedding the biological sample in a first swellable hydrogel; expanding the first swellable hydrogel and the biological sample embedded therein to obtain a first expanded biological sample; embedding the first expanded biological sample in a second swellable hydrogel; labeling a DNA molecule in a chromatin in the biological sample with a first dye; expanding the second swellable hydrogel and the first expanded biological sample embedded therein to obtain a second expanded biological sample; acquiring the microscopic image of the second expanded biological sample with a light microscopy technology. Also described is a method of evaluating the effect of a treatment of a biological sample using the imaging method.
This invention relates to compositions comprising physiologic dendritic cells and at least one mRNA. The invention further relates to compositions comprising physiologic dendritic cells and at least one mRNA for use in therapeutic treatment.
This invention relates to compositions comprising physiologic dendritic cells and at least one mRNA. The invention further relates to compositions comprising physiologic dendritic cells and at least one mRNA for use in vaccination.
Antibodies, chimeric antigen receptors (CARs) and other molecules that specifically bind ENPP3 are provided. Host cells, such as immune cells, including the molecules, antibodies, fusion proteins, CARs, nucleic acids encoding them, are also provided. In some forms, the cells are CAR immune cells. In some forms, the CAR immune cells maintain the ability to kill ENPP3+ cancer cells after multiple stimulations. Pharmaceutical compositions including the antibodies, CARs or T cells are also provided. In some forms, the molecule or antibody includes drugs conjugated thereto, has antibody-dependent cell-mediated cytotoxicity (ADCC) activity, complement-dependent cytotoxicity activity (CDC), and/or is a bi-specific engager optionally a T cell engager or NK cell engager. Methods of using the described molecules to treat ENPP3+ cancers are also described.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
92.
COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER
B.G. Negev Technologies and Applications Ltd. (Israel)
Colorado School of Mines (USA)
Inventor
Gilron, Jack
Elimelech, Menachem
Cath, Tzahi
Abstract
Described herein is a reverse osmosis system, comprising: a feed source input, a high pressure feed pump fluidly connected to the feed source input, a reverse osmosis (RO) cascade fluidly connected to the high pressure feed pump; wherein the RO cascade comprises at least one low salt rejection reverse osmosis (LSRRO) stage including a LSRRO membrane and a seawater reverse osmosis (SWRO) stage including a SWRO membrane fluidly connected to the at least one LSRRO stage.
Described herein is a reverse osmosis system, comprising: a feed source input, a high pressure feed pump fluidly connected to the feed source input, a reverse osmosis (RO) cascade fluidly connected to the high pressure feed pump; wherein the RO cascade comprises at least one low salt rejection reverse osmosis (LSRRO) stage including a LSRRO membrane and a seawater reverse osmosis (SWRO) stage including a SWRO membrane fluidly connected to the at least one LSRRO stage.
Also described herein is a reverse osmosis method, comprising: providing the reverse osmosis system of claim 1, inputting a high salinity fluid into the feed source input, increasing the pressure of the high salinity fluid via the high pressure feed pump, performing reverse osmosis via the RO cascade, and collecting at least one of a concentrate and a permeate.
C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
C02F 103/06 - Contaminated groundwater or leachate
In various aspects and embodiments the invention provides a method of treating pain, stress and anxiety in a subject in need thereof, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3:1 and about 6:1 CBD:THC.
Provided herein are a method of parallelizing zero-knowledge (ZK) protocols, an apparatus for parallelizing zero-knowledge (ZK) protocols, and an apparatus for proving zero-knowledge (ZK) protocols. The method includes providing a ZK framework; calculating local and communication costs for each program instruction of a ZK statement; automatically partitioning the ZK statement according to the calculation; and distributing the partitioned ZK statement to a corresponding number of computing cores for parallel proving or verification. The apparatus for parallelizing zero-knowledge (ZK) protocols includes a processor and a memory unit configured to implement the method. The apparatus for proving zero-knowledge (ZK) protocols includes at least two processors, a memory unit, a communication interface, and a ZK statement parallelized according to the method distributed among the at least two processors. Also provided herein is a non-transitory computer readable storage medium storing computer-executable instructions for performing the method.
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
G06F 9/28 - Enhancement of operational speed, e.g. by using several microcontrol devices operating in parallel
A programmably reconfigurable Ising machine. In embodiments, the programmably reconfigurable Ising machine includes a plurality of spin circuits and a reconfigurable routing network. Each spin circuit includes a spin generator and a set of reconfigurable coupling blocks operatively connected to the spin generator. In embodiments, each reconfigurable coupling block includes a coupling switch operatively connected to the spin generator, a variable coupling unit operatively connected to the coupling switch, and a pin operably connected to the variable coupling unit. In embodiments, the coupling switch and the variable coupling unit are connected to memory and are configurable based on a configuration stored in the memory. In embodiments, the reconfigurable routing network is configured to selectively operatively connect two or more spin circuit of the programmably reconfigurable Ising machine via reconfigurable coupling blocks. Connected spin circuits are interdependent.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Krystal, John H.
Yoon, Gihyun
Petrakis, Ismene L.
Abstract
The present application provides pharmaceutical compositions and methods for treating diseases or disorders. The pharmaceutical composition comprises N-methyl-D-aspartate receptor modulator and μ-opioid receptor modulator. The present application also discloses formulations, dosing and administration routes for the pharmaceutical composition. Diseases can be treated by the pharmaceutical composition are also described.
Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
In various aspects and embodiments the invention provides a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of a cytoskeletal tension regulator and an effective amount of a polypeptide having 80% or greater sequence identity to SEQ ID NO: 1 Fas Ligand (FasL).
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
100.
pH LOW INSERTION PEPTIDE TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS
University of Rhode Island Board of Trustees (USA)
YALE UNIVERSITY (USA)
Inventor
Reshetnyak, Yana K.
Andreev, Oleg A.
Moshnikova, Anna
Engelman, Donald M.
Abstract
The invention features a composition comprising a potent cytotoxic compound and a pHILIP® peptide, where, e.g., the cytotoxic compound cannot be used alone due to a lack of targeting. pHILIP® peptide targets cytotoxic compounds to acidic diseased tissue, translocates cytotoxic compounds across plasma membranes into the cytosols of cells in acidic diseased tissues and induces cell death predominantly in the targeted acidic diseased tissue.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
